Upregulation of Checkpoint Ligand Programmed Death-Ligand 1 in Patients with Paroxysmal Nocturnal Hemoglobinuria Explained by Proximal Complement Activation.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
01 03 2022
Historique:
received: 13 01 2021
accepted: 17 12 2021
pubmed: 18 2 2022
medline: 8 3 2022
entrez: 17 2 2022
Statut: ppublish

Résumé

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hemolytic disease driven by impaired complement regulation. Mutations in genes encoding the enzymes that build the GPI anchors are causative, with somatic mutations in the

Identifiants

pubmed: 35173033
pii: jimmunol.2100031
doi: 10.4049/jimmunol.2100031
doi:

Substances chimiques

B7-H1 Antigen 0
CD274 protein, human 0
CD55 Antigens 0
CD59 Antigens 0
Complement C3 0
Complement C5 0
Membrane Proteins 0
phosphatidylinositol glycan-class A protein 0
CD59 protein, human 101754-01-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1248-1258

Informations de copyright

Copyright © 2022 by The American Association of Immunologists, Inc.

Auteurs

Markus Anliker (M)

Central Institute for Medical and Chemical Laboratory Diagnosis, University Hospital, Innsbruck, Austria.

Daniela Drees (D)

Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.
Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden-Württemberg-Hessen and University Hospital of Ulm, Ulm, Germany.

Lorin Loacker (L)

Central Institute for Medical and Chemical Laboratory Diagnosis, University Hospital, Innsbruck, Austria.

Susanne Hafner (S)

Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany.

Andrea Griesmacher (A)

Central Institute for Medical and Chemical Laboratory Diagnosis, University Hospital, Innsbruck, Austria.

Gregor Hoermann (G)

Central Institute for Medical and Chemical Laboratory Diagnosis, University Hospital, Innsbruck, Austria.
MLL Munich Leukemia Laboratory, Munich, Germany.

Vilmos Fux (V)

Central Institute for Medical and Chemical Laboratory Diagnosis, University Hospital, Innsbruck, Austria.

Harald Schennach (H)

Central Institute of Blood Transfusion and Immunology, University Hospital Innsbruck, Innsbruck, Austria.

Paul Hörtnagl (P)

Central Institute of Blood Transfusion and Immunology, University Hospital Innsbruck, Innsbruck, Austria.

Arthur Dopler (A)

Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany.

Stefan Schmidt (S)

Department of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria; and.

Rosa Bellmann-Weiler (R)

Department of Internal Medicine II, Innsbruck Medical University, Innsbruck, Austria.

Günter Weiss (G)

Department of Internal Medicine II, Innsbruck Medical University, Innsbruck, Austria.

Astrid Marx-Hofmann (A)

Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.
Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden-Württemberg-Hessen and University Hospital of Ulm, Ulm, Germany.

Sixten Körper (S)

Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.
Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden-Württemberg-Hessen and University Hospital of Ulm, Ulm, Germany.

Britta Höchsmann (B)

Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.
Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden-Württemberg-Hessen and University Hospital of Ulm, Ulm, Germany.

Hubert Schrezenmeier (H)

Institute of Transfusion Medicine, University of Ulm, Ulm, Germany; christoph.schmidt@uni-ulm.de h.schrezenmeier@blutspende.de.
Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden-Württemberg-Hessen and University Hospital of Ulm, Ulm, Germany.

Christoph Q Schmidt (CQ)

Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany; christoph.schmidt@uni-ulm.de h.schrezenmeier@blutspende.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH